Is there life after technetium: what is the potential for developing new broad-based radionuclides?

Area of Science:

• Nuclear Medicine
• Radiochemistry
• Medical Imaging

Background:

• Radionuclide use in medicine and research is rapidly expanding.
• Nuclear medicine imaging and radiotherapy are established clinical practices.
• Over 13 million US patients undergo radionuclide imaging annually, with one in four hospital patients receiving a radionuclide procedure.

Purpose of the Study:

• To review the current status and future prospects of new radionuclide development for nuclear medicine.
• To address practical challenges in the large-scale production and availability of novel isotopes.
• To assess the potential of new radionuclides to match the widespread use of technetium-99m (99mTc).

Main Methods:

• Review of current literature on radionuclide development.
• Analysis of trends in nuclear medicine towards functional studies and advanced therapies.
• Consideration of production feasibility and reliable availability for new isotopes.

Main Results:

• Technetium-99m (99mTc) dominates current imaging (over 80%) due to its ideal properties.
• Nuclear medicine is evolving towards functional imaging (e.g., PET) and novel therapeutics.
• Several promising new radionuclides are under development for future applications.

Conclusions:

• New radionuclides are essential for the evolution of nuclear medicine beyond current capabilities.
• While no single isotope may fully replace 99mTc, several candidates show significant promise.
• Addressing production and availability challenges is critical for the successful integration of new radionuclides into clinical practice.